Get the Stockscreener App
1.00
2.04%
0.02
After Hours:
1.04
0.04
+4.00%
Therapeuticsmd Inc stock is traded at $1.00, with a volume of 85,873.
It is up +2.04% in the last 24 hours and up +7.53% over the past month.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
See More
Previous Close:
$0.98
Open:
$0.97
24h Volume:
85,873
Relative Volume:
0.16
Market Cap:
$11.30M
Revenue:
$996.00K
Net Income/Loss:
$-6.09M
P/E Ratio:
-1.8868
EPS:
-0.53
Net Cash Flow:
$-9.76M
1W Performance:
-0.99%
1M Performance:
+7.53%
6M Performance:
-39.39%
1Y Performance:
-55.46%
1-Day Range:
$0.921
$1.0277
1-Week Range:
$0.92
$1.0975
52-Week Range:
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
Name
Therapeuticsmd Inc
Sector
Phone
561-961-1900
Address
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.00 | 11.30M | 996.00K | -6.09M | -9.76M | -0.53 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-20 | Downgrade | Jefferies | Hold → Underperform |
| May-19-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-02-19 | Initiated | Guggenheim | Buy |
| Oct-17-19 | Initiated | H.C. Wainwright | Buy |
| Apr-30-19 | Resumed | Noble Capital Markets | Outperform |
| Jun-15-18 | Initiated | JP Morgan | Overweight |
| Sep-08-17 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-11-17 | Upgrade | Oppenheimer | Perform → Outperform |
| May-09-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-22-16 | Resumed | Jefferies | Buy |
| Nov-22-16 | Initiated | Oppenheimer | Outperform |
| Nov-07-16 | Resumed | Guggenheim | Buy |
| Apr-04-16 | Initiated | Goldman | Buy |
| Dec-08-15 | Reiterated | Jefferies | Buy |
| Dec-08-15 | Reiterated | Stifel | Buy |
| Sep-21-15 | Reiterated | Jefferies | Buy |
| Jun-09-15 | Initiated | Guggenheim | Buy |
| Jul-08-14 | Initiated | FBR Capital | Outperform |
| Apr-17-14 | Reiterated | Noble Financial | Buy |
| Jan-28-14 | Reiterated | Noble Financial | Buy |
View All
Therapeuticsmd Inc Stock (TXMD) Latest News
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023) - Yahoo Finance
TherapeuticsMD Reports Improved Financial Performance - TipRanks
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
DEADLINE MONDAY: Levi & Korsinsky, LLP Reminds Shareholders of a Class Action to Recover Losses Suffered by Investors in TherapeuticsMD, Inc. and a Lead Plaintiff Deadline of June 19, 2017 -- TXMD - ACCESS Newswire
TherapeuticsMD Inc. (TXMD) reports earnings - Quartz
TherapeuticsMD Reports Reduced Losses and Revenue Growth - TipRanks
TherapeuticsMD Earnings: Net Loss Slashed by $5.4M as Royalty Strategy Pays Off - Stock Titan
TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting - Business Wire
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Investor Network: TherapeuticsMD, Inc. to Host Earnings Call - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Cosette paying $430M for Mayne's women’s health, dermatology franchise - BioWorld MedTech
How does TXMD’s price to cash per share ratio compare in the market? - US Post News
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
Therapeuticsmd Inc Stock (TXMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):